Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Based upon this RCT, once a COVID-19 patient is hospitalized, treatment with convalescent plasma apparently has little effect on outcomes. James W. Mold, MD, MPH

Free full text

View

Abstract

Objective To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India.

Design Open label, parallel arm, phase II, multicentre, randomised controlled trial.

Setting 39 public and private hospitals across India.

Participants 464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm).

Interventions Participants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart. The presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study.

Main outcome measure Composite of progression to severe disease (PaO2/FiO2 <100 mm Hg) or all cause mortality at 28 days post-enrolment.

Results Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval −0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54).

Conclusion Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity. A priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19.

Trial registration Clinical Trial Registry of India CTRI/2020/04/024775.

Author/s:

Agarwal, Anup, Mukherjee, Aparna, Kumar, Gunjan, Chatterjee, Pranab, Bharnagar, Tarun, Malhotra, Pankaj

Is the antibody testing for COVID-19 in the general population a useful diagnostic tool?

Brian Desmarais — Mon, 13 Jul 2020 16:25:48 +0000

Date Added:

July 13, 2020

Journal/Publication:

OSMA Journal

Publisher:

Oklahoma Medical Association

Publication Date:

May 2, 2020

URL:

Is the antibody testing for COVID-19 in the general population a useful diagnostic tool?

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

Keywords

antibody testing

MeSH

Immunologic Tests

COVID-19 diagnostic testing

This is an in-depth review of the COVID tests available in Oklahoma. James W. Mold, MD, MPH

Free full text

View

Not available.

Author/s:

Chou, A., Wickersham, E., Bratzler, D.W., Drevets, D., Wendelboe, A.M.